GCP
PDLI

GSA Capital Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

GSA Capital Partners’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,114
Closed -$88K – 1484
2020
Q2 		$88K Sell
30,114
-37,723
-56% -$119K 0.05% 500
2020
Q1 		$191K Buy
67,837
+55,702
+459% +$180K 0.05% 772
2019
Q4 		$39K Sell
12,135
-52,619
-81% -$153K ﹤0.01% 1376
2019
Q3 		$140K Sell
64,754
-150,329
-70% -$402K 0.02% 1237
2019
Q2 		$675K Sell
215,083
-22,430
-9% -$72.8K 0.08% 478
2019
Q1 		$884K Sell
237,513
-7,187
-3% -$24.3K 0.09% 355
2018
Q4 		$710K Sell
244,700
-84,400
-26% -$232K 0.08% 377
2018
Q3 		$866K Sell
329,100
-101,000
-23% -$248K 0.05% 766
2018
Q2 		$1.01M Buy
430,100
+37,824
+10% +$106K 0.05% 748
2018
Q1 		$1.15M Buy
392,276
+35,095
+10% +$95.8K 0.06% 566
2017
Q4 		$979K Sell
357,181
-343,900
-49% -$1.06M 0.06% 607
2017
Q3 		$2.38M Sell
701,081
-93,200
-12% -$259K 0.16% 104
2017
Q2 		$1.96M Sell
794,281
-828,500
-51% -$1.91M 0.13% 165
2017
Q1 		$3.68M Buy
1,622,781
+35,025
+2% +$77.5K 0.2% 62
2016
Q4 		$3.37M Buy
1,587,756
+66,532
+4% +$186K 0.2% 55
2016
Q3 		$5.1M Buy
1,521,224
+199,073
+15% +$632K 0.27% 23
2016
Q2 		$4.15M Buy
1,322,151
+417,127
+46% +$1.39M 0.23% 34
2016
Q1 		$3.01M Sell
905,024
-36,712
-4% -$114K 0.19% 67
2015
Q4 		$3.33M Buy
941,736
+228,013
+32% +$954K 0.16% 101
2015
Q3 		$3.59M Sell
713,723
-241,130
-25% -$1.38M 0.18% 78
2015
Q2 		$6.14M Buy
954,853
+390,418
+69% +$2.62M 0.24% 37
2015
Q1 		$3.97M Buy
564,435
+237,251
+73% +$1.72M 0.16% 88
2014
Q4 		$2.52M Buy
327,184
+607
+0.2% +$4.8K 0.18% 86
2014
Q3 		$2.44M Buy
326,577
+83,705
+34% +$777K 0.13% 157
2014
Q2 		$2.35M Buy
242,872
+108,800
+81% +$970K 0.11% 200
2014
Q1 		$1.11M Buy
134,072
+15,784
+13% +$135K 0.08% 284
2013
Q4 		$998K Sell
118,288
-141,513
-54% -$1.19M 0.08% 362
2013
Q3 		$2.07M Buy
259,801
+35,343
+16% +$284K 0.16% 115
2013
Q2 		$1.73M Buy
+224,458
New +$1.75M 0.21% 86

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GSA Capital Partners's PDLI Position: Q3 2020 in Review

GSA Capital Partners sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 30,114 shares — an estimated $88K sold.

GSA Capital Partners first reported a position in PDLI in Q2 2013 and held it in 29 quarters. The position peaked at $6.14M in Q2 2015. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • GSA Capital Partners reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • GSA Capital Partners sold 30,114 PDL BioPharma, Inc. shares in Q3 2020, an estimated $88K.
  • GSA Capital Partners first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 29 quarters.
  • GSA Capital Partners's PDL BioPharma, Inc. position peaked at $6.14M in Q2 2015.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on GSA Capital Partners's 13F filing for Q3 2020, filed 6 Nov 2020.